It took almost exactly 11 months for FDA to finalize its decision to pull Roche /Genentech Inc. 's Avastin (bevacizumab) metastatic breast cancer indication.
Like everything else in the first-of-its-kind “streamlined withdrawal” process, that sets a precedent.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?